Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Gilead Sciences, Inc. (Nasdaq: GILD) today announced the discontinuation of the Phase 3 KEYNOTE-D46/EVOKE-03 study investigating Gilead’s Trodelvy ® (sacituzumab govitecan-hziy) in c…
Market Samachar is a news aggregator. This article was originally published by Merck.com. Tap the button above to read the full story on their site.